It's undeniable that businesses are facing economic uncertainty in 2023. Here's what marketing tools to tap into to navigate the challenges ahead. Photo via Getty Images

All indications point to a fair amount of economic uncertainty in the coming months. I think a lot of B-to-B companies, across many industries, are going to retrench in their spending, and deals will likely be harder to close because more approvals will be required. Still, there are going to be those companies who will continue to grow because they are using the right go to market strategies and tactics.

Here are some of the things for high growth company management teams to consider doing.

Invest in a CRM tool — and the time to set it up

A customer relations management, or CRM, tool is an essential component of data measurement — and every company needs to closely track those key performance indicators towards revenue and growth goals.

A CRM tool doesn’t have to be expensive. There are many low initial investment options such as Hubspot, SharpSpring, and others. The investment then becomes the staff or consultant time to set it up correctly so that it meets a company’s needs and to continue to monitor it.

How much time is spent depends on what you want the system to do. Some companies run their website out of a CRM platform, or send automated emails, or do their other social media through it. Others only use it to track their contacts and sales.

Data may show desired progress — or it may show stagnation — and a team needs to be able to analyze information expediently to reformulate a plan, or pivot to a new one, if needed.

Prioritize the digital toolkit

While companies have a lot of different digital marketing tools at their disposal, there are five basic elements to consider optimizing. If the resources aren’t available to tackle them all at once, the management team needs to determine their top priorities.

Website design and content: Think about this as a company’s virtual lobby. A well-designed website with relevant content is essential for attracting new business. Ranking well in organic web searches — SEO — is also a very important component.

Social media: LinkedIn, with its business focus, is a great place to start. Companies can share their story, interact with potential investors, and build relationships with potential clients.

Email marketing: An email marketing newsletter is the logical step after developing a compelling company website. The content should benefit the reader. What can you do for them?

Content marketing: Blog posts, videos and ebooks are just some of the value added content you can share with potential investors and clients. What makes your company different from your competitors?

Paid advertising: Companies can use paid advertising to target potential new customers through online channels such as search engines and social media. The nice thing about paid advertising is that the attribution is there — companies can pinpoint exactly what messaging resonated with a potential client.

Let goals drive strategy

SEO and digital ads are not the solution for every company. Some companies need to make only a handful of deals each year to reach revenue goals. Broad-based digital marketing is not the best strategy for these players. What is? Often content.

The internet has given potential customers unparalleled ability to comparison shop. They want to know what a company does differently than its competitors. Whether a service or product is cheaper or faster or easier to work with. So tell them.

In addition to web content, speaking opportunities at conferences are a powerful way for companies to position themselves as differentiated in a given marketplace.

On the flip side, high volume players who require a lot of smaller deals would do very well with a far-reaching digital outreach approach.

Listen to experts

No one is an expert in all areas. And they shouldn’t try to be. Whether that is financial analysis or digital marketing, hiring the right people to fill in any deficiencies is the smart move.

Trying to wing it through effort and good intentions is often frustrating for everyone. With digital marketing and lead generation, a lack of expertise can sometimes result in implementing a product or service that’s not really going to generate the expected results.

If a company spends big money on a digital marketing tactic, and it fails to land new business, then the assumption might be that digital marketing doesn’t work. That’s often not the case. It was simply the wrong tool for the job. An expert would help pinpoint the correct one.

Measure success first by revenue

Digital marketing should primarily be responsible for moving potential customers down the sales funnel. And sales revenue is the best evidence that the marketing was effective.

There has always been that push and pull with sales and marketing about what actions actually contribute to closing a deal but a good CRM tool will help.

There are other ways to measure the success of any campaign:

  • The number of visitors to a company’s website or social media page
  • The level of engagement a campaign generates or the amount of time a prospect engages with content
  • The number of leads generated, along with the quality of that lead
  • The return on investment

Continued growth starts with goal setting and coming up with a marketing and business development strategy that fits the unique needs of a business. This works most effectively when a company’s management team ensures that marketing and sales are working in lockstep. They are two sides of the same coin and need to see themselves that way to maximize results and therefore profit.

------

Libby Covington is partner at Houston-based The Craig Group, a strategic digital marketing solutions consulting firm. Her specialty is in understanding how sales and marketing work together effectively.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston startups named most innovative in Texas by LexisNexis

report card

Three Houston companies claimed spots on LexisNexis's 10 Most Innovative Startups in Texas report, with two working in the geothermal energy space.

Sage Geosystems claimed the No. 3 spot on the list, and Fervo Energy followed closely behind at No. 5. Fintech unicorn HighRadius rounded out the list of Houston companies at No. 8.

LexisNexis Intellectual Property Solutions compiled the report. It was based on each company's Patent Asset Index, a proprietary metric from LexisNexis that identifies the strength and value of each company’s patent assets based on factors such as patent quality, geographic scope and size of the portfolio.

Houston tied with Austin, each with three companies represented on the list. Caris Life Sciences, a biotechnology company based in Dallas, claimed the top spot with a Patent Asset Index more than 5 times that of its next competitor, Apptronik, an Austin-based AI-powered humanoid robotics company.

“Texas has always been fertile ground for bold entrepreneurs, and these innovative startups carry that tradition forward with strong businesses based on outstanding patent assets,” Marco Richter, senior director of IP analytics and strategy for LexisNexis Intellectual Property Solutions, said in a release. “These companies have proven their innovation by creating the most valuable patent portfolios in a state that’s known for game-changing inventions and cutting-edge technologies.We are pleased to recognize Texas’ most innovative startups for turning their ideas into patented innovations and look forward to watching them scale, disrupt, and thrive on the foundation they’ve laid today.”

This year's list reflects a range in location and industry. Here's the full list of LexisNexis' 10 Most Innovative Startups in Texas, ranked by patent portfolios.

  1. Caris (Dallas)
  2. Apptronik (Austin)
  3. Sage Geosystems (Houston)
  4. HiddenLayer (Austin)
  5. Fervo Energy (Houston)
  6. Plus One Robotics (San Antonio)
  7. Diligent Robotics (Austin)
  8. HighRadius (Houston)
  9. LTK (Dallas)
  10. Eagle Eye Networks (Austin)

Sage Geosystems has partnered on major geothermal projects with the United States Department of Defense's Defense Innovation Unit, the U.S. Air Force and Meta Platforms. Sage's 3-megawatt commercial EarthStore geothermal energy storage facility in Christine, Texas, was expected to be completed by the end of last year.

Fervo Energy fully contracted its flagship 500 MW geothermal development, Cape Station, this spring. Cape Station is currently one of the world’s largest enhanced geothermal systems (EGS) developments, and the station will begin to deliver electricity to the grid in 2026. The company was recently named North American Company of the Year by research and consulting firm Cleantech Group and came in at No. 6 on Time magazine and Statista’s list of America’s Top GreenTech Companies of 2025. It's now considered a unicorn, meaning its valuation as a private company has surpassed $1 billion.

Meanwhile, HighRadius announced earlier this year that it plans to release a fully autonomous finance platform for the "office of the CFO" by 2027. The company reached unicorn status in 2020.

---

This article originally appeared on Energy Capital HTX.

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.